The global stem cell therapy market is expected to grow at a CAGR of 16.5 percent to USD 401 million by 2026, up from USD 187 million in 2021. Due to the growing production of stem cell-based therapies, government initiatives for developing regenerative medicines, the establishment of many stem cell banks, and increasing clinical trials for regenerative medicines in the region, Asia Pacific is expected to grow at the fastest CAGR of 9.0 percent during the forecast year. For example, MEDIPOST, Korea announced the results of NEUROSTEM's phase 1/2a study in July 2020. It's an experimental stem cell therapy for the treatment of Alzheimer's disease.
To combat the pandemic, researchers have been developing new therapies and treatments. Stem cells have been shown to be an effective treatment for pulmonary disorders, like COVID-19, in recent years.
In addition, the increasing number of product development initiatives in this field, combined with the presence of several marketed products, has resulted in a significant increase in overall cell therapy manufacturing demand. As a result, cell therapy developers have turned to contract manufacturing organizations (CMOs) to meet their growth and production needs.
These opportunities include contract research and manufacturing outsourcing and rising patient population with neurological and other chronic conditions in the region. China, Japan, Singapore, and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming year.
Adult stem cell leads the market due to low contamination during sub-culture and expansion, relatively small labor production and compatibility with the human body. Just the Induced pluripotent stem cells (IPSc’s) was expected to report revenue of over USD 4.5 billion by 2020, on account of the similar nature of its origin. With the continued growth of medical tourism hubs like India, Singapore, and Thailand, Asia is expected to maintain its place as the epicenter of stem cell research and therapy. These opportunities include contract research outsourcing and rising patient population with neurological and other chronic conditions in the region. Japan, Singapore, and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming years.
Zhimei Du Merck & Co
Pascal Touchon Atara Biotherapeutics
Ivan D. Horak Tessa Therapeutics Pte Ltd
John Rossi CERo Therapeutics, Inc.
Rafi Emmanuel Emendo Biotherapeutics
Hemant Chamne Immuneel Therapeutics Pvt Ltd
Joy (Shuxia) Zhou Takeda
Gregory Fiore Exacis Biotherapeutics
Shashwati Basak Immuneel Therapeutics Ltd
Chien-Tsun Kuan ARCE Therapeutics Inc.
Lee Buckler RepliCel Life Sciences
Dror Harats VBL Therapeutics
Hardy TS Kagimoto Healios
Magali Taiel GenSight Biologics
Vibha Jawa Bristol Myers Squibb
Nicholas Huntington oNKo Innate
Mark Aspinall-O’Dea Retrogenix
Paul Lammers Triumvira Immunologics
Devyn Smith Arbor Biotechnologies
Seong-Wook Lee Rznomics Inc.
Yu Zhang VCANBIO Cell & Gene Engineering
Yuan Zhao National Institute for Biological Standards and Control (NIBSC)
Technology Showcase Sponsor
Cell & Gene Therapy World Asia will provide commercial organizations with the opportunity to educate the market about what to offer. It will help you in terms of leadership roles in the field alongside crucial industry figures. Host innovative round – table sessions of up to 20 industry professionals around critical topics and exclusive workshops/master-class of up to 50 end- users. Therefore, raising brand awareness will be an advantage and enjoy the option of privately arranged meetings and consultations with selected potential clients. Also, you will get the chance to hold face to face meetings with your target profile.